Oncolytic Adenovirus Market Growth Opportunities: Insights from 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Oncolytic Adenovirus Market Over The Five-Year Period 2025–2029?

The oncolytic adenovirus market size has seen substantial growth recently. It is projected to increase from $122.31 billion in 2024 to $132.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. The expansion observed in the past can be ascribed to a higher incidence of cancer, the escalating need for precise cancer treatments, increased investment in research and development, advancements in delivery techniques, and successful regulatory clearances.

The oncolytic adenovirus market size is projected to experience strong growth over the next few years. It is expected to expand to $181.71 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.2%. The anticipated growth during this period can be attributed to the increasing prevalence and incidence of cancer, the expansion of combination therapies, advancements and approvals in regulations, technological improvements in virus engineering, and greater investment in oncology research. Significant trends identified for the forecast period include innovations in viral engineering techniques, sophisticated drug delivery systems, enhanced precision in tumor targeting, advanced immunotherapy combinations, and progress in patient monitoring and diagnostics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Which Drivers Are Supporting Growth Of The Oncolytic Adenovirus Market?

The future expansion of the oncolytic adenovirus market is anticipated to be significantly driven by the rising occurrence of cancer. Cancer, a condition where cells grow uncontrollably and spread throughout the body, is becoming more prevalent due to factors such as an aging global population, various lifestyle choices, environmental exposures, inherited genetic tendencies, and enhanced diagnostic methods. Oncolytic adenovirus presents a hopeful strategy for addressing this growing cancer incidence by specifically targeting and eliminating cancer cells. For example, in May 2024, data from the National Cancer Institute (NCI), a U.S. government body, indicated approximately 20 million new cancer cases and 9.7 million deaths globally, with forecasts suggesting an increase to 29.9 million cases and 15.3 million deaths by 2040. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government entity, reported that 1.8% of Australians were living with cancer, with males (2.1%) being marginally more affected than females (1.6%), particularly individuals aged 75 and over. Consequently, the increasing frequency of cancer diagnoses is a key driver for the growth within the oncolytic adenovirus market.

What Are The Segment Types Shaping The Oncolytic Adenovirus Market?

The oncolytic adenovirusmarket covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types

2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications

3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based

3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses

Which Ongoing Trends Are Expected To Shape The Oncolytic Adenovirus Market Outlook?

Leading companies within the oncolytic adenovirus market are increasingly concentrating on combination therapies, exemplified by VCN-01. This approach integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic results. VCN-01 itself is an oncolytic adenovirus specifically engineered to selectively infect and destroy cancer cells, concurrently boosting the efficacy of chemotherapy. Illustratively, Theriva Biologics, a US-based clinical-stage immuno-oncology firm, announced in May 2024 that the U.S. Food and Drug Administration (FDA) had bestowed Fast Track Designation (FTD) upon its primary candidate, VCN-01. This FTD applies to VCN-01’s use alongside gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. Furthermore, VCN-01 functions as an oncolytic adenovirus by targeting and replicating within tumor cells, thereby aiding in the degradation of the tumor stroma, which is a significant impediment to effective cancer therapy.

Who Are The Core Companies Influencing The Oncolytic Adenovirus Market Landscape?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

What Are The Key Regional Factors Influencing The Oncolytic Adenovirus Market Growth?

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Oncolytic Adenovirus Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2025, By The Business Research Company

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

Herpes Simplex Virus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/herpes-simplex-virus-treatment-global-market-report

Human Papillomavirus Hpv Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/human-papillomavirus-hpv-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795